| Literature DB >> 33967478 |
Krishna Sireesha Sundaragiri1, Abikshyeet Panda2.
Abstract
COVID-19 pandemic is an event to remember; it has unequivocally affected every part of our lives both ways. It has opened up numerous research areas with abundant funding opportunities and avenues; oral research is just a small part of this research world. In this review, we look into oral research in the COVID-19 era and India's position in COVID-19 research. The salient features of the National Guidelines for Ethics Committee Reviewing Biomedical and Health Research during the COVID-19 pandemic have been described. Some possible research topics in dentistry during COVID-19 and the need for the impetus to the dental community for oral research have been discussed. Copyright:Entities:
Keywords: COVID-19; Indian Council of Medical Research; oral research; research grants
Year: 2021 PMID: 33967478 PMCID: PMC8083428 DOI: 10.4103/jomfp.jomfp_480_20
Source DB: PubMed Journal: J Oral Maxillofac Pathol ISSN: 0973-029X
Figure 1Proposed research areas for COVID-19. Adapted from Haleem et al. 2020[2]
Figure 2Priority research areas in dentistry
An overview of ICMR guidelines for Ethics Committee Reviewing Biomedical and Health Research during COVID-19 pandemic
| General principles |
| Four basic principles for guiding biomedical and health research: Respect for person, beneficence, nonmaleficence and justice |
| General ethical issues |
| Consider benefit-risk. Based on type of risk involved, consider the review required as exempted, expedited or full committee |
| Maintain privacy confidentiality of highly sensitive COVID-19 infection information |
| Regard distributive justice for inclusion in the research without social, racial or ethnic inequalities and conflict of interest (financial/nonfinancial) of researcher, EC members, institution and sponsors |
| Include payment for participation and compensation for research-related harm- financial compensation for research-related SAE through insurance, corpus funds or grants. SAE should be reported to EC within 24 h and a report on SAE relatedness (casualty) within 14 days for quantum and assistance review |
| Community engagement should be in a culturally sensitive manner, educate the public about pandemic (COVID-19), research, risk, etc. |
| Storage of COVID-19 samples with adequate safeguards with clarity on custodianship and EC approval |
| Collaborate for rapid data sharing while safeguarding data is critical. Foreign assistance/collaboration will need the Health Ministry’s screening committee approval before initiation |
| Focused research on public health system preparedness and interventions to prevent, delay or contain spread |
| Note sociobehavioral harm in COVID-19 disaster from isolation, quarantine, segregation from families |
| Design alternative studies – online or remote methods. Consider that technological requirements may exclude participants without access to technology. Virtual tools for data collection must be assessed for privacy and security features by EC (case to case basis) |
| Identify constraints for fast track conduct of research |
| Agencies and sponsors need to ensure safety, care, compensation, funds and training for all engaged (at individual, societal or community level) in COVID-19 research along with preparation of public education material |
| Undertake expeditious review for clinical trial for new drugs and use approved MEURI |
| Facilitate posttrial access of successful investigational drug/vaccine free of cost to participants till same is available in the market |
| Responsible role of media in facilitating dissemination of useful information and not create panic |
| SARS-CoV-2 virus isolation and characterization should be conducted in a BSL-3 or BSL-4 laboratories as prescribed by the Department of Biotechnology and Ministry of Environment and Forests, Government of India |
| Telemedicine with necessary patient consent for research when possible |
| Ethical review procedures |
| Three categories of research: new research directly related to COVID-19, ongoing non-COVID research and new non-COVID research |
| EC must prioritize research review based on urgency and in view of social distancing norms |
| EC |
| Ensure a thorough scientific and ethical review, re-review and plan next steps for fast track review |
| EC to be registered with appropriate agencies |
| DHR - biomedical and health research |
| CDSCO - clinical trials as per new drug and clinical trial rules 2019 |
| All COVID-19 related research to be registered on CTRI |
| EC could have a quorum of minimum of five members including medical/nonmedical or technical/nontechnical members with one nonaffiliated member |
| If members of local EC are unavailable, the review may be conducted by any other EC within India for initiating the study until local EC can convene its meeting |
| Special situations can be multiple EC, registered independent EC or institutional subcommittees that report to the main EC |
| Research proposals should be submitted as soft/hard copy in ICMR common forms for Ethics Review ( |
| The EC adopts an SOP for emergency research review, plan prior review by experts and shorten timelines for accelerated procedure of electronic documents |
| Short agendas, frequent virtual video conference meetings for fast track review within 24–48 h |
| Considerations for written consent not possible in severe or isolated COVID-19 patients. Use of oral or electronic methods (via phone) to document and record consent and identify SAE |
| Maintaining right balance to protect privacy and disclosure of relevant information |
| Maintaining digital recording of meeting, online voting for decision-making by members |
| Common review for multicenter research in India by one main designated EC |
| Ensuring strict monitoring and oversight by local ECs |
| Continuing review and monitoring |
| The EC should continually evaluate progress of ongoing proposals, monitor approved study site for compliance, review SAE reports, protocol deviations/violations/noncompliance/DSMB reports/any new information/assess final reports |
| For protocol deviations/violations the EC should examine the corrective actions. If the violations are serious, the EC may halt the study and compensation be given |
| Ongoing and existing studies - Consider the impact risk of COVID-19 ongoing study recruitment and continued involvement of participants. Consider extension, temporary halt at some/all sites; suspension/postponement of study or activation of sites that have not yet been initiated without compromising safety and well-being of patients |
| New non-COVID research studies treatment evaluations of chronic conditions or communicable diseases or injuries also need equal consideration. Suggestions for additional safeguards for research |
| Informed consent document |
| Challenges in obtaining consent from COVID-19 patients, hospitalized patients, children |
| Use of broad consent with an individual informed opt-out option may be used for research on residual clinical samples |
| Electronic consent |
| Use of technology and electronic tools of text, graphics, audio, video, podcasts, etc. |
| Electronic methods (digital signature) will need EC approval priori |
| Wavier of consent with adequate rationale in retrospective studies, anonymized data, public health studies, data in public domain, humanitarian emergencies when participant not in position to give consent |
| Vulnerability |
| Individuals/certain groups of persons who are incapable of protecting their own interests such as COVID-19 patients, socially, economically or politically disadvantaged, health-care workers in COVID-19 hospitals, terminally ill, unduly influenced or lack of autonomy |
| Ensuring additional safeguards for participants and prevent stigmatization |
| Ensuring safety of researcher/health-care worker is responsibility of the institution, sponsors and local authorities |
| Prioritize research and schedules to prevent overcrowding |
| Adequate training |
| Appropriate biosafety precautions |
| Expose minimum number of researchers |
| Communication using electronic platforms |
| Use protection gear/PPE and facilities to undertake research |
| Safety against any assault from public or others |
| Insurance cover |
| Provide support for psychological needs and maintain good mental health and well-being of COVID-19 patients and their families |
SAE: Serious adverse events, EC: Ethics committee, MEURI: Monitored emergency use of unregistered and experimental interventions, SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, BSL: Biosafety level, DHR: Department of Health Research, CDSCO: Central drug standard control organization, CTRI: Clinical trial registry of India, ICMR: Indian Council of Medical Research, SOP: Standard operating procedure, DSMB: Data and safety monitoring board, PPE: Personal protective equipment
Hot topics for dental research in COVID-19 era
| Saliva detection kits, validation of technique |
| Disease transmission – aerosols |
| Economical masks and respirators, validation in real time setting |
| Protocols in high risk setting dental operatory |
| Technological aspects of sterilization (UV), shields, high volume suction, air purifiers, ventilation systems |
| Teledentistry |
| Dental caries vaccine |
UV: Ultraviolet